Signage for GlaxoSmithKline is seen on it's offices in London, Britain (Copyright Reuters 2017)
A major British drugmaker is recalling more than 593,000 asthma inhalers from U.S. hospitals, pharmacies, retailers and wholesalers after receiving a number of complaints about leakage and packaging. GSK Plc said there are concerns that the Ventolin asthma may deliver fewer doses of the medicine than indicated, Reuters reported.
DOES ILLNESS HELP YOUNG ADULTS TAKE CHARGE OF THEIR OWN HEALTH?
The defect does not pose an immediate danger to patients, so consumers are not being instructed to return already purchased inhalers. The U.S. Food and Drug Administration (FDA) approved the recall, Reuters reported.
GSK said the company is working to identify the cause of the problem, but the company’s main plant is continuing to produce the inhalers.
GIRL SUFFERS FATAL ASTHMA ATTACK HOURS AFTER BEING SENT AWAY BY DOCTOR, REPORT SAYS
“We currently don’t anticipate a supply impact to Ventolin HFA 200D inhaler as a result of this issue,” GSK said in a statement, according to Reuters.
Reuters contributed to this report.
Stay up-to-date on the biggest health and wellness news with our weekly recap.